Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Rachel Soon, 05 Dec 2020

The Malaysian National Immunisation Programme (NIP) will now include a hexavalent combination DTaP-IPV-HiB-HepB vaccine and a pneumococcal vaccine.

Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.

Pulmonary rehabilitation makes difference in COPD patients

01 Dec 2020

A pulmonary rehabilitation (PR) programme for chronic obstructive pulmonary disease (COPD) yields sustained improvements in anxiety and quality of life of patients over 2 years, a study has shown. However, the positive changes in dyspnoea, depression, and stress symptoms may only last short term.

The study population comprised 165 COPD patients (mean age, 72 years; 55 percent male) who completed an 8-week, community-based, comprehensive PR programme. This intervention involved 2-hour sessions held twice weekly. During sessions, patients performed aerobic exercise and attended an educational programme. Patients were also encouraged to perform daily walking exercise up to 30 minutes at home.

At week 8 weeks, the patients showed significant improvements in several parameters. These included  dyspnoea (measured using the modified Medical Research Council questionnaire), quality of life (assessed using Saint George’s Respiratory Questionnaire), exercise capacity (measured with the Incremental Shuttle Walk Test), anxiety (evaluated using the Anxiety Inventory for Respiratory Disease), and the Depression Anxiety Stress Scale (p<0.001 for all).

Without a maintenance programme, changes seen at 8 weeks persisted for only anxiety symptoms and quality of life over the 2-year follow-up.

On multivariable analysis, initial elevated levels of dyspnoea, depression, and anxiety and decreased exercise capacity significantly predicted sustained improvement in quality of life (p<0.001 for all).

Additional studies comparing a well-designed maintenance programme with no maintenance following PR are warranted to determine whether maintenance programmes can widen the range and magnitude of beneficial outcomes over the long term.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Rachel Soon, 05 Dec 2020

The Malaysian National Immunisation Programme (NIP) will now include a hexavalent combination DTaP-IPV-HiB-HepB vaccine and a pneumococcal vaccine.

Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.